Ganirelix and the prevention of premature luteinizing hormone surges

Ganirelix is a gonadotropin-releasing hormone (GnRH) antagonist with high antagonistic activity that blocks the GnRH receptor by competitive binding. A daily dose of 0.25 mg of ganirelix was sel5ected after a phase II study because it was the minimal, effective daily dose to prevent premature lutein...

Descripción completa

Detalles Bibliográficos
Autor principal: Mannaerts, Bernadette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Special Issue
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10201301/
https://www.ncbi.nlm.nih.gov/pubmed/37223764
http://dx.doi.org/10.1016/j.xfre.2023.02.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10201301/
https://www.ncbi.nlm.nih.gov/pubmed/37223764
http://dx.doi.org/10.1016/j.xfre.2023.02.009

Ejemplares similares